Cellectar Biosciences Stock Z Score
| CLRB Stock | USD 1.52 0.02 1.30% |
Cellectar | Z Score |
Cellectar Biosciences Company Z Score Analysis
Cellectar Biosciences' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Cellectar Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Cellectar Biosciences is extremely important. It helps to project a fair market value of Cellectar Stock properly, considering its historical fundamentals such as Z Score. Since Cellectar Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cellectar Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cellectar Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
In accordance with the company's disclosures, Cellectar Biosciences has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Cellectar Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cellectar Biosciences' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cellectar Biosciences could also be used in its relative valuation, which is a method of valuing Cellectar Biosciences by comparing valuation metrics of similar companies.Cellectar Biosciences is currently under evaluation in z score category among its peers.
Cellectar Biosciences Institutional Holders
Institutional Holdings refers to the ownership stake in Cellectar Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cellectar Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cellectar Biosciences' value.| Shares | Bank Of America Corp | 2024-06-30 | 63.1 K | Northern Trust Corp | 2024-09-30 | 61.1 K | Xtx Topco Ltd | 2024-09-30 | 53 K | Jane Street Group Llc | 2024-06-30 | 41.9 K | Raymond James Finl Svs Advisors, Inc. | 2024-09-30 | 30 K | Pale Fire Capital Se | 2024-09-30 | 25 K | Sequoia Financial Advisors Llc | 2024-09-30 | 23.8 K | Jpmorgan Chase & Co | 2024-09-30 | 23.2 K | Two Sigma Securities, Llc | 2024-09-30 | 22.8 K | Rosalind Advisors, Inc. | 2024-09-30 | 3.7 M | Aigh Capital Management, Llc | 2024-09-30 | 3.2 M |
Cellectar Fundamentals
| Return On Equity | -7.97 | ||||
| Return On Asset | -1.66 | ||||
| Current Valuation | 42.6 M | ||||
| Shares Outstanding | 41.27 M | ||||
| Shares Owned By Insiders | 2.83 % | ||||
| Shares Owned By Institutions | 34.54 % | ||||
| Number Of Shares Shorted | 1.16 M | ||||
| Price To Earning | (1.35) X | ||||
| Price To Book | 40.49 X | ||||
| EBITDA | (38.77 M) | ||||
| Net Income | (37.98 M) | ||||
| Cash And Equivalents | 24.81 M | ||||
| Cash Per Share | 4.06 X | ||||
| Total Debt | 552.98 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 4.51 X | ||||
| Book Value Per Share | (0.96) X | ||||
| Cash Flow From Operations | (32.38 M) | ||||
| Short Ratio | 8.34 X | ||||
| Earnings Per Share | (1.41) X | ||||
| Target Price | 13.33 | ||||
| Number Of Employees | 20 | ||||
| Beta | 1.01 | ||||
| Market Capitalization | 62.73 M | ||||
| Total Asset | 12.08 M | ||||
| Retained Earnings | (217.48 M) | ||||
| Working Capital | (2.48 M) | ||||
| Current Asset | 8.14 M | ||||
| Current Liabilities | 1.39 M | ||||
| Net Asset | 12.08 M |
About Cellectar Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cellectar Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectar Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectar Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cellectar Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cellectar Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cellectar Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cellectar Biosciences Stock:Check out Cellectar Biosciences Piotroski F Score and Cellectar Biosciences Valuation analysis. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.41) | Return On Assets (1.66) | Return On Equity (7.97) |
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.